Industries > Pharma > Global Treatment for Neglected Tropical Disease Market 2019-2029

Global Treatment for Neglected Tropical Disease Market 2019-2029

Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease

PUBLISHED: 21 May 2019
PAGES: 157
PRODUCT CODE: PHA0396

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0240 Categories: , , Tag:

The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere.

The 157-page report provides clear detailed insight into the Global Treatment for Neglected Tropical Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Treatment for Neglected Tropical Disease market forecasts from 2019-2029

Global Treatment for Neglected Tropical Disease Market 2017-2027

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by disease type:
– Malaria treatments
– Dengue treatments
– Leishmaniasis
– Schistosomiasis
– Lymphatic Filariasis
– Chagas Disease
– Others

For each disease type, the report provides a SWOT analysis, a list of selected drugs and revenue forecasts from 2019-2029 of the leading drugs.

• This report provides revenue forecast for these leading drugs:
– Coartem (Novartis)
– Clindamycin (Pfizer)
– Dengvaxia (Sanofi)
– AmBisome (Gilead Sciences)
– Impavido (Knight Therapeutics)
– ALBENZA (Amedra Pharmaceuticals LLC)

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by regional and national market:
– North America: US and Canada
– Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
– Asia-Pacific: Japan, China, India, Rest of Asia
– Latin America: Brazil, Mexico, Rest of Latin America
– Middle East & Africa: Saudi Arabia, South of Africa, Rest of Middle East & Africa

Each regional market is further broken down by disease type.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the neglected tropical disease market:
– Pfizer, Inc.
– Bayer
– GlaxoSmithKline plc
– Merck & Co., Inc.
– Novartis International AG
– Takeda Pharmaceutical Company Ltd
– Sanofi S.A.
– Eisai Co., Ltd

Buy our report today Global Treatment for Neglected Tropical Disease Market 2019-2029: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Latest Pharma news

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

READ

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

READ

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

READ

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

READ

Categories

Category